- Switzerland
- /
- Food and Staples Retail
- /
- SWX:DOCM
Is Zur Rose Group's (VTX:ROSE) Share Price Gain Of 210% Well Earned?
Unfortunately, investing is risky - companies can and do go bankrupt. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Zur Rose Group AG (VTX:ROSE) share price has soared 210% in the last year. Most would be very happy with that, especially in just one year! On top of that, the share price is up 58% in about a quarter. And shareholders have also done well over the long term, with an increase of 181% in the last three years.
See our latest analysis for Zur Rose Group
Because Zur Rose Group made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.
Zur Rose Group grew its revenue by 8.9% last year. That's not great considering the company is losing money. So we wouldn't have expected the share price to rise by 210%. The business will need a lot more growth to justify that increase. It's quite likely that the market is considering other factors, not just revenue growth.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
This free interactive report on Zur Rose Group's balance sheet strength is a great place to start, if you want to investigate the stock further.
A Different Perspective
It's nice to see that Zur Rose Group shareholders have gained 210% (in total) over the last year. That gain actually surpasses the 41% TSR it generated (per year) over three years. These improved returns may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 2 warning signs for Zur Rose Group you should be aware of.
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on CH exchanges.
If you decide to trade Zur Rose Group, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About SWX:DOCM
DocMorris
Operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally.
Fair value with mediocre balance sheet.